However, patients treated with crizotinib typically develop resistance within a year or two, and there is a higher incidence of central nervous system (CNS) progression or metastasis in ALK‐positive NSCLC patients who receive crizotinib as a first‐line treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.